Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT06022328 | Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)(EpiC) | recruiting | — | 120 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 |
| clinicaltrials |
| NCT06458257 | The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia | recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | recruiting | Phase 2 | 50 | Beijing 302 HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05237258 | Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia(SCOPE-L) | recruiting | N/A | 2,300 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05703542 | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 24 | Eric Stephen Winer, MDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML(PEARL) | recruiting | Phase 2 | 160 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants(CML) | recruiting | Phase 1 | 21 | Enliven TherapeuticsINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT04687176 | Frontline Oral Arsenic Trioxide for APL | recruiting | Phase 2 | 100 | The University of Hong KongOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Hangzhou Weben Pharma Co., LtdINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | recruiting | Phase 2 | 30 | The University of Hong KongOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07007949 | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | recruiting | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06119269 | Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase(PHOENICS) | recruiting | — | 100 | University of PisaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06130579 | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT | recruiting | Phase 2 | 35 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06390306 | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | recruiting | — | 30 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06982274 | Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia(IC-APL2020) | recruiting | Phase 2 | 115 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06696183 | Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment(SEQUENCE) | recruiting | Phase 2 | 60 | Technische Universität DresdenOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | recruiting | Early Phase 1 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06869265 | Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia | recruiting | Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06138990 | Pharmacoscopy-guided Clinical Standard-of-care in r/r AML(RAPID-01) | recruiting | Phase 2 | 88 | ETH ZurichOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05124288 | Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways(GITMO-RELAPSE) | recruiting | — | 500 | Ciceri FabioOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT06752746 | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | recruiting | Phase 1 | 108 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT06947044 | Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding(BAIT) | recruiting | N/A | 60 | Donald ArnoldOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial(MAST) | recruiting | Phase 2 | 50 | Imperial College LondonOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06537726 | Breath Analysis for the Detection of Invasive Fungal Infections(REDEFINE) | recruiting | — | 130 | University of ZurichOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03439371 | Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia(MTSA) | recruiting | N/A | 21 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05130138 | Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia(PHARM-LMC) | recruiting | N/A | 100 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05282108 | Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia(CARCML) | recruiting | — | 240 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06022003 | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia(OGILAR) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06891144 | Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy | recruiting | — | 1,000 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06892223 | Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation | recruiting | Phase 2 | 42 | Istituto Clinico HumanitasOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06245746 | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | recruiting | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06885476 | Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients | recruiting | N/A | 22 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04314219 | Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients(PTCy-PMAT) | recruiting | Phase 3 | 264 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06874257 | Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade | recruiting | — | 20 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2025source: clinicaltrials